Cite
Pexidartinib plus FLT3-directed CAR-Macrophage for the treatment of FLT3-ITD-mutated acute myeloid leukemia in preclinical model.
MLA
“Pexidartinib plus FLT3-Directed CAR-Macrophage for the Treatment of FLT3-ITD-Mutated Acute Myeloid Leukemia in Preclinical Model.” Cancer Weekly, Oct. 2024, p. 790. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=180199674&authtype=sso&custid=ns315887.
APA
Pexidartinib plus FLT3-directed CAR-Macrophage for the treatment of FLT3-ITD-mutated acute myeloid leukemia in preclinical model. (2024). Cancer Weekly, 790.
Chicago
“Pexidartinib plus FLT3-Directed CAR-Macrophage for the Treatment of FLT3-ITD-Mutated Acute Myeloid Leukemia in Preclinical Model.” 2024. Cancer Weekly, October, 790. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=180199674&authtype=sso&custid=ns315887.